The global multimodal imaging systems market is expected to grow at a CAGR of 5.3% from 2018 to reach $1,574.8 million by 2024.
Multimodal imaging combines the innate advantages of the fused imaging technologies synergistically, forming more powerful imaging modality. It combines techniques such as such as Computed Tomography (CT), Magnetic Resonance Imaging (MRI), and Positron Emission Tomography (PET) to accurately identify the diseased and the normal tissues. For instance, combination of PET or Single-Photon Emission Computed Tomography (SPECT) and CT imaging, overcomes the low resolution of the PET or SPECT image with the high resolution of CT image. In addition, this combination provides high sensitivity to the procedure, enabling accurate diagnosis. Due to these benefits, the leading players are consistently launching new systems in the market. In 2017, Siemens Healthineers, a part of Siemens AG (Germany) launched Biograph Vision PET/CT system with reduced crystal elements, offering higher spatial resolution that improves lesion detectability in cancer diagnosis.
In addition to diagnosis, this technique is also used in small animal imaging for drug discovery and development procedures. The technique helps in understanding dynamic biological processes, gene expression, enzyme and protein activity, progression, treatment of diseases, biodistribution, pharmacodynamics or pharmacokinetics of drug molecule in model organisms. Such imaging data assist researchers in the study of the fundamental aspects of human system function and dysfunction. Key players like Bruker Corporation (U.S.), MR Solutions Ltd. (U.K.), and PerkinElmer, Inc. (U.S.) are providing pre-clinical multimodal imaging systems for research applications. In 2018, Bruker Corporation (U.S.) introduced new preclinical PET/CT Si78 scanner for whole-body preclinical imaging with homogeneous, high-resolution, and quantitative PET/CT imaging with a large field of view. Also, in 2018, MR Solutions Ltd. (U.K.) launched pre-clinical CT scan models for sequential multimodal imaging with MRI and CT scanners.
The global multimodal imaging systems market is segmented by product (multimodal imaging equipment, reagents, and software), technology (PET/CT, SPECT/CT, PET/MRI, and others), application (clinical applications and research applications), end user (hospitals, diagnostic centers, academic & research institutes, and others), and geography.
Based on the technology type, PET/CT segment commanded the largest share of the global multimodal imaging systems market in 2018, mainly attributed to high resolution, sensitivity, and efficiency of this technology in detection of tumor lesions.
Based on the application type, clinical applications segment commanded the largest share of the global multimodal imaging systems market in 2018. The large share of this application segment is attributed to rise in volume of imaging services, increased demand by patients and physicians, and technological advances in imaging technologies.
Geographically, this market is segmented in to North America (U.S. and Canada), Europe (Germany, France, U.K., Spain, Italy, and RoE), Asia-Pacific (Japan, China, India and RoAPAC), Latin America, and Middle East & Africa. North American region dominated the global multimodal imaging systems market in 2018, followed by Europe and Asia-Pacific. The large share of the North American region is attributed to the well-established healthcare system in the region, greater adoption of advanced technologies, growing prevalence of chronic diseases, presence of large number of hospitals, growing aging population, and relatively greater access to healthcare.
The global multimodal imaging systems market is concentrated with leading companies occupying one-third of the market share. The key players operating in this market are GE Healthcare (U.S.), Siemens AG (Germany), Koninklijke Philips N.V. (the Netherlands), Mediso Ltd. (Hungary), Canon Inc. (Japan), PerkinElmer, Inc. (U.S.), Bruker Corporation (U.S.), MR Solutions Ltd. (U.K.), Northridge Tri-Modality Imaging, Inc. (U.S.), Shanghai United Imaging Healthcare Co., Ltd. (China), and MILabs B.V. (the Netherlands).
Scope of the Report:
Market by Product
- Multimodal imaging equipment
- Reagents
- Software
Market by Technology
- PET/CT
- SPECT/CT
- PET/MRI
- Others
Market by Application
- Clinical applications
- ·Oncology
- ·Cardiology
- ·Neurology
- ·Orthopedics
- ·Others
- Research applications
Market by End user
- Hospital
- Diagnostic centers
- Academic & research institutes
- Others
Market by Geography
North America
- ·U.S.
- ·Canada
Europe
- ·Germany
- ·France
- ·U.K.
- ·Spain
- ·Italy
- ·Rest of Europe (RoE)
Asia-Pacific (APAC)
- ·Japan
- ·China
- ·India
- ·Rest of APAC (RoAPAC)
Latin America
Middle East & Africa